Linzagolix for treating moderate to severe symptoms of uterine fibroids

NICE has produced a resource impact template that incorporates the following technology appraisal guidance for symptoms of endometriosis and uterine fibroids:

• Linzagolix for treating symptoms of endometriosis (2025) NICE technology appraisal guidance 1067
• Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (2025) NICE technology appraisal guidance 1057
• Linzagolix for treating moderate to severe symptoms of uterine fibroids (2024) NICE technology appraisal guidance 996
• Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (2022) NICE technology appraisal guidance 832